

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

Recombinant Anti-PD1 antibody [EPR4877(2)]

RRID:AB_2894867

Type: Antibody

Proper Citation

Abcam Cat# ab137132, RRID:AB_2894867

Antibody Information

URL: http://antibodyregistry.org/AB_2894867

Proper Citation: Abcam Cat# ab137132, RRID:AB_2894867

Target Antigen: PD1

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: IHC-P

Antibody Name: Recombinant Anti-PD1 antibody [EPR4877(2)]

Description: This recombinant monoclonal targets PD1

Target Organism: human

Clone ID: EPR4877(2)

Antibody ID: AB_2894867

Vendor: Abcam

Catalog Number: ab137132

Record Creation Time: 20231110T031614+0000

Record Last Update: 20260901T062157+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-PD1 antibody [EPR4877(2)].

No alerts have been found for Recombinant Anti-PD1 antibody [EPR4877(2)].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Xu Y, et al. (2026) Ultra-precision deconvolution of spatial transcriptomics decodes immune heterogeneity and fate-defining programs in tissues. *Nature communications*, 17(1).

Pham FK, et al. (2026) Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy. *Journal for immunotherapy of cancer*, 14(6).

Naing A, et al. (2026) Biomarker study of pembrolizumab in patients with advanced rare cancers. *Cell reports. Medicine*, 7(6), 102827.

Zhou J, et al. (2026) Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma. *Cell host & microbe*, 34(4), 639.

Schiantarelli J, et al. (2025) Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. *Cancer cell*, 43(2), 308.

Schalck A, et al. (2025) The impact of breast radiotherapy on the tumor genome and immune ecosystem. *Cell reports*, 44(5), 115703.

Morris VK, et al. (2025) Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(9), 1657.

Li H, et al. (2025) Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. *Cancer cell*, 43(4), 757.

How JA, et al. (2025) Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. *Med (New York, N.Y.)*, 6(1), 100494.

Cakmak P, et al. (2025) Spatial immune profiling defines a subset of human gliomas with functional tertiary lymphoid structures. *Immunity*, 58(11), 2847.

Mukund K, et al. (2025) Spatially distinct cellular and molecular landscapes define prognosis in triple-negative breast cancer. *Cell reports*, 45(1), 116752.

Chen Z, et al. (2024) YTHDF2-mediated circYAP1 drives immune escape and cancer progression through activating YAP1/TCF4-PD-L1 axis. *iScience*, 27(2), 108779.

Lee KJ, et al. (2024) IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy. *Cell reports. Medicine*, 5(5), 101567.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.

Campbell MJ, et al. (2024) Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. *Cell reports. Medicine*, 5(11), 101799.

Tang Z, et al. (2023) Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer. *Cell reports. Medicine*, 4(2), 100931.

Yadavilli S, et al. (2023) Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. *Cancer research communications*, 3(8), 1564.

Liu Z, et al. (2023) Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. *Cancer cell*, 41(11), 1852.

Huang Q, et al. (2023) MTFR2 shapes a barrier of immune microenvironment in hepatocellular carcinoma. *iScience*, 26(1), 105095.

Xu-Monette ZY, et al. (2023) Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(23), 4808.